The UK's advertising regulator has prohibited five dietary supplement campaigns that made therapeutic claims about addressing menopause symptoms, polycystic ovarian syndrome, and hormonal imbalances in women.

Four brands—222 Balance Me, Lunera, Minerva, and Nova Menopause Vitality—faced enforcement action for marketing their nutritional supplements as capable of preventing, treating, or alleviating menopausal symptoms.

Separately, PolyBiotics' promotional materials and website suggested their formulations could address PCOS, prompting regulatory intervention.

The Advertising Standards Authority emphasized its heightened scrutiny of marketing that potentially exploits consumers' health anxieties, emotional vulnerabilities, or economic constraints.

These enforcement actions stem from an AI-assisted monitoring initiative that scanned health-related advertising claims online, uncovering persistent and emerging patterns of potentially misleading promotional content.

According to the watchdog, numerous assertions within the advertisements violated multiple advertising standards and posed risks by potentially misleading vulnerable consumers or discouraging them from seeking appropriate medical consultation.

In its response to the ASA, 222 Collective characterized itself as an emerging founder-led enterprise still navigating the complexities of advertising compliance frameworks.

The company conceded that certain language in their promotional materials may have unintentionally suggested therapeutic efficacy for conditions including PMS, menopausal symptoms, anxiety, bloating, menorrhagia, and mood disturbances.

The firm indicated it has since collaborated with Trading Standards to eliminate both explicit and implicit claims regarding disease treatment or symptom management.

Lunera acknowledged that consumers would reasonably interpret its marketing claims as attributing medicinal properties to a food supplement product, which should not have been communicated.

PolyBiotics informed the ASA that it recognized references to PCOS, ovulation, fertility, cycle regulation, insulin resistance, and associated symptoms constituted impermissible disease treatment or symptom-management representations for dietary supplements.

Neither Minerva nor Nova provided responses to the regulator's inquiries.

Catherine Drewett, investigations manager at the ASA, stated: "Consumers navigating women's health concerns require transparent and evidence-based information.

"Marketing communications that misrepresent treatment capabilities for menopausal symptoms, PCOS, and other hormonal conditions present genuine consumer protection concerns. Today's determinations establish accountability standards for advertisers in this category.

"Our monitoring of this sector will remain active, and we welcome reports from anyone who encounters questionable advertising claims."